Drug Details

General Information of the Drug (ID: DR7903)
Name
SLC-0111
Synonyms
178606-66-1; U-104; 4-(3-(4-fluorophenyl)ureido)benzenesulfonamide; 1-(4-fluorophenyl)-3-(4-sulfamoylphenyl)urea; SLC-0111; mst-104; 4-{[(4-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; NSC213841; CHEMBL1615281; Carbonic Anhydrase IX/XII Inhibitor II(U-104); 4-{[(4'-Fluorophenyl)Carbamoyl]Amino}Benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide; 4-[3-(4-Fluorophenyl)ureido]benzenesulfonamide; WWZ; NSC 213841; 3n4b; SCHEMBL672955; GTPL10149; AOB5732; EX-A904; SLC0111; HMS3651H21; HMS3872E13; BCP14895; ZINC1752601; BDBM50334354; MFCD00159265; s2866; 4-fluorophenylureido-benzenesulfonamide; AKOS001123930; CCG-267573; compound 7 [PMID: 21361354]; CS-4495; MCULE-4710078413; NSC-213841; SB19580; NCGC00379154-03; AC-32932; AK341046; AS-66547; HY-13513; FT-0699833; SW220124-1; U 104; U-104, >=98% (HPLC); U-104;NSC213841;MST104; X5935; A14959; J-690246; (3?,5?)-3,14,17-Trihydroxycard-20(22)-enolide; 3-(4-FLUOROPHENYL)-1-(4-SULFAMOYLPHENYL)UREA; Q27467365; 4-(((4-Fluoroanilino)carbonyl)amino)benzenesulfonamide; 4-{[(4''-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzesulfonamide
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C13H12FN3O3S
PubChem CID
310360
Canonical SMILES
C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F
InChI
1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)
InChIKey
YJQZNWPYLCNRLP-UHFFFAOYSA-N
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          3-O-acetylbetulin      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Enhancement DNA damage
Enhancement Radiosensitivity
                    In-vitro Model MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
MDA-231 Breast cancer Homo sapiens
                    Experimental
                    Result(s)		 The combined treatment with 3-AC and CAI strongly enhanced radiosensitivity, increased cytotoxicity, inhibited cell motility and enhanced DNA damage.
Target and Pathway
Target(s) Interleukin 2 receptor alpha (IL2RA)  Molecule Info  [3]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
2 Endocytosis
3 PI3K-Akt signaling pathway
4 Jak-STAT signaling pathway
5 Hematopoietic cell lineage
6 Measles
7 HTLV-I infection
NetPath Pathway IL5 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
3 IL2 Signaling Pathway
4 TNFalpha Signaling Pathway
5 Leptin Signaling Pathway
Panther Pathway Interleukin signaling pathway Click to Show/Hide
Pathway Interaction Database IL12-mediated signaling events Click to Show/Hide
2 Calcineurin-regulated NFAT-dependent transcription in lymphocytes
3 Arf6 trafficking events
4 SHP2 signaling
5 IL2-mediated signaling events
6 IL2 signaling events mediated by PI3K
7 IL2 signaling events mediated by STAT5
8 Calcium signaling in the CD4+ TCR pathway
9 Downstream signaling in na&#xef
10
11 IL12 signaling mediated by STAT4
Reactome GPVI-mediated activation cascade Click to Show/Hide
2 G beta:gamma signalling through PI3Kgamma
3 Interleukin-2 signaling
4 RAF/MAP kinase cascade
5 Interleukin receptor SHC signaling
WikiPathways IL-2 Signaling Pathway Click to Show/Hide
2 Inflammatory Response Pathway
3 Interleukin-2 signaling
4 Allograft Rejection
5 TSLP Signaling Pathway
6 IL-7 Signaling Pathway
7 Interleukin-3, 5 and GM-CSF signaling
References
Reference 1 ClinicalTrials.gov (NCT02215850) Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
Reference 2 Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chem Biol Interact. 2021 Jan 5;333:109326.
Reference 3 Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol. 2012 Jan;142(1):9-14.
 Download Picture         KEGG Link